That all depends on the numbers.
Let’s for arguments sake say ultimately Cydy will be worth (all in millions) 3,000 (combi )+ 200 (prostate test) + 0 (for all the rest, nuts of course).
Worst case current shareholders will get diluted 100/700 (currently autorized shares 600 increased to 700).
This in return for 45 million (current share price x 100).
Current shareholders will then end up having 600/700 x 3,200 = 2,743
Should Cydy decide to ‘give away’ the prostate test for let’s say 45 million (while it being worth 200) million, the current shareholders will end up with 3,000.
While from the company’s point of view it would make not sense to sell something below value (in this case 155 less) from the current shareholders point of view it makes perfect sense (they would be better off 253 by doing just that)
People can use all the numbers they would like. The higher the value of the company, the more it makes sense from a current shareholders point of view to sell a company’s asset below its value if that provides the funds needed to realize that end value.
Just for entertainment: if the company would ultimately be worth 20,000 current shareholders would miss 2,857 (something like $5 for each share) for the company’s decision not to sell the prostate test 155 below it’s value (“costs” for the current shareholders something like $0,26).
Market Data 
Markets 
